Immunogenicity of SARS-CoV: the Receptor-Binding Domain of S Protein is a Major Target of Neutralizing Antibodies

This publication has 14 references indexed in Scilit:

• SARS Vaccine Development
  Emerging Infectious Diseases, 2005
• Vaccine Design for Severe Acute Respiratory Syndrome Coronavirus
  Viral Immunology, 2005
• Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines
  Virology, 2005
• Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine
  Published by Elsevier ,2004
• Identification of Immunodominant Sites on the Spike Protein of Severe Acute Respiratory Syndrome (SARS) Coronavirus: Implication for Developing SARS Diagnostics and Vaccines
  The Journal of Immunology, 2004
• Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection
  The Journal of Infectious Diseases, 2004
• Mucosal immunisation of African green monkeys ( Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
  The Lancet, 2004
• Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice
  Proceedings of the National Academy of Sciences, 2004
• Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors
  Published by Elsevier ,2004
• A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2
  Journal of Biological Chemistry, 2004